156 related articles for article (PubMed ID: 8502954)
1. [Cytokines and lymphoplasmocytic proliferations: essential role of interleukin 6].
Bataille R; Klein B
Rev Prat; 1993 Feb; 43(3):275-8. PubMed ID: 8502954
[TBL] [Abstract][Full Text] [Related]
2. Cytokine network in human multiple myeloma.
Klein B; Bataille R
Hematol Oncol Clin North Am; 1992 Apr; 6(2):273-84. PubMed ID: 1582974
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma.
Klein B; Zhang XG; Jourdan M; Boiron JM; Portier M; Lu ZY; Wijdenes J; Brochier J; Bataille R
Eur Cytokine Netw; 1990; 1(4):193-201. PubMed ID: 2104241
[TBL] [Abstract][Full Text] [Related]
4. IFN-alpha induces autocrine production of IL-6 in myeloma cell lines.
Jourdan M; Zhang XG; Portier M; Boiron JM; Bataille R; Klein B
J Immunol; 1991 Dec; 147(12):4402-7. PubMed ID: 1753108
[TBL] [Abstract][Full Text] [Related]
5. Cooperation between heparin-binding EGF-like growth factor and interleukin-6 in promoting the growth of human myeloma cells.
Wang YD; De Vos J; Jourdan M; Couderc G; Lu ZY; Rossi JF; Klein B
Oncogene; 2002 Apr; 21(16):2584-92. PubMed ID: 11971193
[TBL] [Abstract][Full Text] [Related]
6. Disruption by interferon-alpha of an autocrine interleukin-6 growth loop in IL-6-dependent U266 myeloma cells by homologous and heterologous down-regulation of the IL-6 receptor alpha- and beta-chains.
Schwabe M; Brini AT; Bosco MC; Rubboli F; Egawa M; Zhao J; Princler GL; Kung HF
J Clin Invest; 1994 Dec; 94(6):2317-25. PubMed ID: 7989587
[TBL] [Abstract][Full Text] [Related]
7. Tumor necrosis factor is a survival and proliferation factor for human myeloma cells.
Jourdan M; Tarte K; Legouffe E; Brochier J; Rossi JF; Klein B
Eur Cytokine Netw; 1999 Mar; 10(1):65-70. PubMed ID: 10210775
[TBL] [Abstract][Full Text] [Related]
8. Establishment and characterization of three myeloma cell lines that demonstrate variable cytokine responses and abilities to produce autocrine interleukin-6.
Westendorf JJ; Ahmann GJ; Greipp PR; Witzig TE; Lust JA; Jelinek DF
Leukemia; 1996 May; 10(5):866-76. PubMed ID: 8656685
[TBL] [Abstract][Full Text] [Related]
9. Roles of protein phosphatase 1 and 2A in an IL-6-mediated autocrine growth loop of human myeloma cells.
Kang HS; Lee BS; Yang Y; Park CW; Ha HJ; Pyun KH; Choi I
Cell Immunol; 1996 Mar; 168(2):174-83. PubMed ID: 8640863
[TBL] [Abstract][Full Text] [Related]
10. Growth regulatory pathways in myeloma. Evidence for autocrine oncostatin M expression.
Westendorf JJ; Jelinek DF
J Immunol; 1996 Oct; 157(7):3081-8. PubMed ID: 8816418
[TBL] [Abstract][Full Text] [Related]
11. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
Hideshima T; Neri P; Tassone P; Yasui H; Ishitsuka K; Raje N; Chauhan D; Podar K; Mitsiades C; Dang L; Munshi N; Richardson P; Schenkein D; Anderson KC
Clin Cancer Res; 2006 Oct; 12(19):5887-94. PubMed ID: 17020997
[TBL] [Abstract][Full Text] [Related]
12. Delineation of the roles of paracrine and autocrine interleukin-6 (IL-6) in myeloma cell lines in survival versus cell cycle. A possible model for the cooperation of myeloma cell growth factors.
Jourdan M; Mahtouk K; Veyrune JL; Couderc G; Fiol G; Redal N; Duperray C; De Vos J; Klein B
Eur Cytokine Netw; 2005; 16(1):57-64. PubMed ID: 15809207
[TBL] [Abstract][Full Text] [Related]
13. Expression and production of interleukin 10 in human myeloma cell lines.
Otsuki T; Yamada O; Yata K; Sakaguchi H; Kurebayashi J; Yawata Y; Ueki A
Br J Haematol; 2000 Dec; 111(3):835-42. PubMed ID: 11122145
[TBL] [Abstract][Full Text] [Related]
14. Interleukin 1 autocrine growth system in human multiple myeloma.
Nagata K; Tanaka Y; Oda S; Yamashita U; Eto S
Jpn J Clin Oncol; 1991 Feb; 21(1):22-9. PubMed ID: 2067118
[TBL] [Abstract][Full Text] [Related]
15. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma.
Alexandrakis MG; Passam FH; Boula A; Christophoridou A; Aloizos G; Roussou P; Kyriakou DS
Ann Hematol; 2003 Jan; 82(1):19-23. PubMed ID: 12574959
[TBL] [Abstract][Full Text] [Related]
16. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.
Lauta VM
Cancer; 2003 May; 97(10):2440-52. PubMed ID: 12733143
[TBL] [Abstract][Full Text] [Related]
17. IFN-alpha is a survival factor for human myeloma cells and reduces dexamethasone-induced apoptosis.
Ferlin-Bezombes M; Jourdan M; Liautard J; Brochier J; Rossi JF; Klein B
J Immunol; 1998 Sep; 161(6):2692-9. PubMed ID: 9743325
[TBL] [Abstract][Full Text] [Related]
18. Acquisition of growth autonomy and tumorigenicity by an interleukin 6-dependent human myeloma cell line transfected with interleukin 6 cDNA.
Okuno Y; Takahashi T; Suzuki A; Fukumoto M; Nakamura K; Fukui H; Koishihara Y; Ohsugi Y; Imura H
Exp Hematol; 1992 May; 20(4):395-400. PubMed ID: 1568457
[TBL] [Abstract][Full Text] [Related]
19. Establishment of a novel myeloma cell line KPMM2 carrying t(3;14)(q21;q32), which proliferates specifically in response to interleukin-6 through an autocrine mechanism.
Goto H; Shimazaki C; Tatsumi T; Yamagata N; Fujita N; Tsuchiya M; Koishihara Y; Ohsugi Y; Nakagawa M
Leukemia; 1995 Apr; 9(4):711-8. PubMed ID: 7723407
[TBL] [Abstract][Full Text] [Related]
20. Effects of all-trans retinoic acid and antireceptor antibodies on growth and programmed cell death of human myeloma cells.
Taetle R; Dos Santos B; Akamatsu K; Koishihara Y; Ohsugi Y
Clin Cancer Res; 1996 Feb; 2(2):253-9. PubMed ID: 9816167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]